Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 37
Inquire Before Buying

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline landscape.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the touch, fever and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development
Destiny Pharma Ltd
MGB Biopharma Ltd
Syntiron LLC
Techulon Inc
Valevia UK Ltd
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Drug Profiles
Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Staphylococcus aureus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones
Featured News & Press Releases
Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Ltd, H1 2018
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd, H1 2018
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Syntiron LLC, H1 2018
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon Inc, H1 2018
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Valevia UK Ltd, H1 2018
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, H1 2018
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Heparin calcium (CAS 37270-89-6) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 141
    The global market size of Heparin calcium is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Heparin calcium Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Heparin calcium industry. The key insights of the report: 1.The report provides key statistics on the marke......
  • Global Diclofenac Sodium (CAS 15307-79-6) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 139
    The global market size of Diclofenac Sodium is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Diclofenac Sodium Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Diclofenac Sodium industry. The key insights of the report: 1.The report provides key statistics on the......
  • Global Meclofenamic Acid (CAS 15307-86-5) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 137
    The global market size of Meclofenamic Acid is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Meclofenamic Acid Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Meclofenamic Acid industry. The key insights of the report: 1.The report provides key statistics on the......
  • Global Phenformin Hydrochloride (CAS 834-28-6) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 135
    The global market size of Phenformin Hydrochloride is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Phenformin Hydrochloride Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Phenformin Hydrochloride industry. The key insights of the report: 1.The report provides ......
  • Global Rosiglitazone Maleate (CAS 155141-29-0) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 135
    The global market size of Rosiglitazone Maleate is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Rosiglitazone Maleate Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Rosiglitazone Maleate industry. The key insights of the report: 1.The report provides key stati......
  • Global Glibenclamide (CAS 10238-21-8) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 145
    The global market size of Glibenclamide is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Glibenclamide Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Glibenclamide industry. The key insights of the report: 1.The report provides key statistics on the market stat......
  • Global Amlodipine (CAS 88150-42-9) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 147
    The global market size of Amlodipine is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Amlodipine Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Amlodipine industry. The key insights of the report: 1.The report provides key statistics on the market status of the......
  • Global Nitrendipin (CAS 39562-70-4) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 135
    The global market size of Nitrendipin is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Nitrendipin Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Nitrendipin industry. The key insights of the report: 1.The report provides key statistics on the market status of ......
  • Global Minoxidil Sulfate (CAS 60628-96-8) Market Report 2019 - Market Size, Share, Price, Trend and Forecast
    Published: 22-Jan-2019        Price: US 4000 Onwards        Pages: 143
    The global market size of Minoxidil Sulfate is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. Global Minoxidil Sulfate Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Minoxidil Sulfate industry. The key insights of the report: 1.The report provides key statistics on the......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs